Effect of brofaromine and pargyline on human plasma melatonin concentrations.
1. Plasma melatonin was used to determine the influence of two monoamine oxidase inhibitor drugs in 11 normal subjects. 2. Acute oral administration of the selective reversible MAO-A inhibitor brofaromine but not of the - in low doses - selective MAO-B inhibitor pargyline increased daytime melatonin with large variations in onset, degree and duration. 3. Further investigation of this selective action on melatonin might help to better understand the action of the therapeutically effective antidepressive therapy with selective MAO-A inhibitors.
Bieck
P R
PR
Human Pharmacology Institute, CIBA-GEIGY Tübingen, FRG.
Antonin
K H
KH
Balon
R
R
Oxenkrug
G
G
D000284:Administration, Oral; D000328:Adult; D002940:Circadian Rhythm / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008550:Melatonin / Q000097:blood*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D010293:Pargyline / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*
D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; C038213:brofaromine; D010293:Pargyline; D008550:Melatonin